So, here’s what you need to know:
☑️ Drug discovery is becoming a factory. The competitive moat isn't the smartest AI model - it's the automation, the feedback loop, the throughput. Build repeatable design-build-test-learn engines fusing computational models with automated labs, or get left behind.
☑️ Under “what leaders are underestimating,” the report states flatly: “Agentic biology is now real.” AI systems that sense, decide, and execute in closed loops - not as demos, but as operating infrastructure. The report calls treating this as “just biotech R&D” a category error.
☑️ Virtual cells got its own section. The report names Geneformer, TranscriptFormer, Xaira, and NVIDIA's Virtual Cell Challenge as real efforts toward simulating how cells respond to drugs computationally. The fact that this concept has graduated from academic conferences to boardroom strategy documents tells you the direction we're going in.
☑️ The report gestures at data as a bottleneck but undersells how specific the problem is. It's not just that biology needs more data. It's that data diversity - not model size - may be the binding constraint on progress. The models getting the best results right now aren't always the biggest ones. (3/4)